INVESTORS & MEDIA

23rd Congress of the European Hematology Association (EHA)

Jun 15, 2018 at 5:30 PM CDT


Additional Information

Atara Biotherapeutics and its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) will present long-term clinical outcomes for patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLD) who failed first line treatment and were subsequently treated with tab-cel™ (tabelecleucel) in Phase 2 studies. The poster will be featured during the upcoming 23rd Congress of the European Hematology Association (EHA), which will be held in Stockholm, Sweden, June 14-17, 2018.

 

View press release and abstract

 

Details for the poster presentations are as follows:

 

Abstract PF401: Long Term Outcomes of Tabelecleucel (Allogeneic Third-Party EBV-Targeted Cytotoxic Tn Lymphocytes) for Rituximab-Refractory Post-Transplant EBV+ Lymphomas: A Single Center Experience

 

Session Title: Gene therapy, cellular immunotherapy and vaccination - Clinical

 

Presentation Date & Time: Friday, June 15; 5:30 p.m. to 7:00 p.m. CEST

 

Authors:Susan Prockop, Ekaterina Doubrovina, Amy Feng, Guenther Koehne, Parastoo Dahi, Esperanza Papadopoulos, Craig Sauter, Stephanie Suser, Willis Navarro, Akshay Sudhindra, Richard O'Reilly

 

Location: Poster area, Älvsjö building, Stockholm International Fairs and Congress Centre (Stockholmsmässan)